Allegra-D generic
This article was originally published in The Tan Sheet
Executive Summary
Barr receives ANDA approval for the first generic version of Sanofi-Aventis' Allegra-D 12-hour tablets, (fexofenadine HCl/pseudoephedrine HCl extended release), FDA announces April 14. A launch would be "at risk" due to pending patent litigation with Sanofi-Aventis over both Allegra and Allegra-D formulations. Barr recently prevailed in a dispute with Impax, gaining 180-day exclusivity of generic Allegra-D. Sanofi-Aventis plans to launch a 24-hour formulation later this year...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.